Unknown

Dataset Information

0

Targeting ERBB2 (HER2) Amplification Identified by Next-Generation Sequencing in Patients With Advanced or Metastatic Solid Tumors Beyond Conventional Indications.


ABSTRACT: PURPOSE:Human epidermal growth factor receptor 2 (HER2) is an effective therapeutic target in breast and gastric and gastroesophageal junction cancers. However, less is known about the prevalence of ERBB2 (HER2) amplification and the efficacy of HER2-targeted treatment in other tumors. PATIENTS AND METHODS:We assessed HER2 amplification status among 5,002 patients with advanced disease (excluding breast cancer) who underwent next-generation sequencing. We evaluated the clinical benefit of HER2-targeted therapy by measuring the time-dependent overall survival (OS) from the genomic testing results, progression-free survival (PFS), and PFS during HER2-targeted therapy (PFS2) compared with PFS during prior therapy (PFS1). RESULTS:Overall, 122 patients (2.4%) had HER2 amplification, including patients with endometrial (5.3%), bladder (5.2%), biliary or gallbladder (4.9%), salivary (4.7%), and colorectal cancer (3.6%). Forty patients (38%) with nongastric, nongastroesophageal junction, or nonesophageal cancers received at least one line of HER2-targeted therapy. Patients receiving HER2-targeted therapy had a median OS of 18.6 months, compared with 10.9 months for patients who did not receive HER2-targeted therapy (P = .070). On multivariable analysis, HER2-targeted therapy was significantly associated with increased OS (hazard ratio, 0.5; 95% CI, 0.27 to 0.93; P = .029), regardless of sex, age, or number of prior lines of treatment. The PFS2-to-PFS1 ratio was 1.3 or greater in 21 (57%) of 37 patients who received HER2-targeted therapy not in the first line of systemic treatment, and the median PFS2 and PFS1 times were 24 and 13 weeks, respectively (P < .001). CONCLUSION:HER2 amplifications using next-generation sequencing can be identified in a variety of tumor types. HER2-targeted therapy may confer clinical benefit in tumor types other than those for which HER2 inhibitors are approved.

SUBMITTER: Dumbrava EEI 

PROVIDER: S-EPMC7446516 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature

altmetric image

Publications


<h4>Purpose</h4>Human epidermal growth factor receptor 2 (HER2) is an effective therapeutic target in breast and gastric and gastroesophageal junction cancers. However, less is known about the prevalence of <i>ERBB2</i> (<i>HER2</i>) amplification and the efficacy of HER2-targeted treatment in other tumors.<h4>Patients and methods</h4>We assessed <i>HER2</i> amplification status among 5,002 patients with advanced disease (excluding breast cancer) who underwent next-generation sequencing. We eval  ...[more]

Similar Datasets

| S-EPMC5314454 | biostudies-literature
| S-EPMC6498841 | biostudies-literature
| S-EPMC9325965 | biostudies-literature
| S-EPMC6019182 | biostudies-literature
| S-EPMC6019715 | biostudies-literature
| S-EPMC7954749 | biostudies-literature
| S-EPMC7190903 | biostudies-literature
| S-EPMC8897871 | biostudies-literature
| S-EPMC6896712 | biostudies-literature
| S-EPMC4763101 | biostudies-literature